Augustine Therapeutics key facts
as of Oct 2026- Developer of therapeutic drugs designed to treat neuromuscular and neurodegenerative diseases.
- Augustine Therapeutics is valued at approximately $73.5M as of Oct 2026 (last reported valuation).
- It has raised $93.4M; the latest was Later Stage VC ($83.3M) in Mar 2025.
- Notable investors include Novo Holdings, Participatiemaatschappij Vlaanderen, Asabys Partners, Eli Lilly and Company Foundation, VIB — 14 tracked in total.
- Status: Privately Held (backing).
Augustine Therapeutics's last reported valuation, Mar 2025. Nothing priced has surfaced since.
- ·The complete investor list: 14 names
- ·Watch Augustine Therapeutics: the Monday email on marks, rounds and moves
Augustine Therapeutics funding rounds
No funding rounds for Augustine Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Augustine Therapeutics
14+Augustine Therapeutics valuation
Augustine Therapeutics's last reported valuation was $73.5 million in Mar 2025. No priced round, secondary trade or fund mark has surfaced since.
Augustine Therapeutics investors
14 investors are on record for Augustine Therapeutics, including Novo Holdings, Participatiemaatschappij Vlaanderen, Asabys Partners and Eli Lilly and Company Foundation.
About Augustine Therapeutics
Developer of therapeutic drugs designed to treat neuromuscular and neurodegenerative diseases. The company's drugs have the potential to protect from nerve degeneration and promote peripheral myelin repair, enabling healthcare providers to improve the lives of patients and cure them.
- Sector
- Healthcare
- HQ
- Leuven, Belgium
- Founded
- 2019
- Employees
- 23
- Website
- augustinetx.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.